Search Results - "Heffernan, M.P."

Features that define clinical severity of ulcerative pyoderma gangrenosum – a Delphi consensus study of experts and patients on behalf of the United States Medical Dermatology Society by Pimentel, M.A., Li, M.M., Noe, M.H., Latour, E., Seminario-Vidal, L., Greiling, T., Shinkai, K., Hamilton, A., Alavi, A., Bolognia, J.L., Cowen, E.W., Dominguez, A., Fernandez, A.P., Fivenson, D., Huang, W.W., Madigan, L.M., Mauskar, M., Means, A.D., Nelson, C.A., Patsatsi, A., Pugliese, D., Rojek, N.W., Rosenbach, M., Smith, G.P., Swerlick, R.A., Heffernan, M.P., Mostaghimi, A., Loayza, A.G. Ortega

Get full text

Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis by Langley, R.G., Rich, P., Menter, A., Krueger, G., Goldblum, O., Dutronc, Y., Zhu, B., Wei, H., Cameron, G.S., Heffernan, M.P.

“…Background Scalp and nail psoriasis have a major impact on quality of life and are traditionally resistant to therapy. Ixekizumab is a monoclonal antibody that…”
Get full text

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab by Edson-Heredia, E., Banerjee, S., Zhu, B., Maeda-Chubachi, T., Cameron, G.S., Shen, W., Heffernan, M.P., Gordon, K.B., Leonardi, C.L.

Get full text

A pilot study of the safety and efficacy of picolinic acid gel in the treatment of acne vulgaris by Heffernan, M.P., Nelson, M.M., Anadkat, M.J.

“…Summary  Background  Cost limitations, adverse effects or lack of efficacy limit the use of current topical therapies in mild to moderate acne vulgaris…”
Get full text